

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Challenging arterial calcification disease associated with rare NT5E gene mutation

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1742980> since 2020-07-04T12:40:08Z

Published version:

DOI:10.1136/bcr-2020-235365

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Challenging arterial calcification disease associated with rare *NT5E* gene mutation

Giampiero Avruscio¹, Mauro Massussi², Angelo Adamo¹, Alfredo Brusco³

1. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Angiology Unit, Padua, Italy.
2. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.
3. Department of Medical Sciences, University of Torino, and Medical Genetics Unit, “Città della Salute e della Scienza” University Hospital, Torino, Italy.

DESCRIPTION

A 47-year-old woman has been suffering from intermittent claudication since she was 33 years. The symptoms have slowly worsened during the following years and the patient was unable to walk more than 200 meters without leg pain (Leriche – Fontain IIb) at admission. She had a history of hydroxyapatite crystal calcification disease diagnosed at the age of 19 years, after the onset of bilateral symmetric hand arthritis and Raynaud phenomenon.

On physical examination peripheral pulses were weak at palpation and ankle-brachial index (ABI) measurement was markedly decreased (0.59 on the right and 0.38 on the left leg). Echo-colour-Doppler ultrasounds of the lower limbs documented severely calcified arteries (**Figure 1A, B**), while no calcification of the carotid walls was found. The patient underwent coronary CT scan, abdominal and thoracic aorta CT scan and lower limbs artery CT scan and X-ray to accurately assess the systemic calcium deposit and to determine the global cardiovascular risk. The images revealed severe calcific arterial disease limited to femoral and popliteal arteries bilaterally with developed collateral neovascularization (**Figure 1C, D**); coronary arteries and the whole aorta were free from vascular wall calcification. Hands X-ray displayed pericapsular calcification of the finger joints. A wide panel of laboratory examination, including serum calcium and phosphate, vitamin-D, parathyroid hormone, anti-nuclear antibodies (ANA), anti-extractable nuclear antigen antibodies (ENA) were unremarkable.

We performed Sanger sequencing the coding exons of the *NT5E* gene (Table) and identified the homozygous c.1608dupA – p.Val537SerfsTer7 variant, consistent with the diagnosis of “Arterial Calcification due to Deficiency of CD73” also known as “CALCification of Joints and Arteries” (CALJA) syndrome (MIM211800). The variant is predicted loss-of-function, described in another case with the disease [1] and reported in ClinVar database (VCV000029689.1). Segregation analysis showed both parents were heterozygotes (Figure 2).

Arterial Calcification due to Deficiency of CD73 is a rare syndrome defined by arterial calcification which targets vessels below the diaphragm, notably the large lower extremity arteries, and spares coronary circulation. Mutations in *NT5E* gene, encoding for the plasma membrane enzyme CD73 which hydrolyses AMP to adenosine and inorganic phosphate (Pi), were identified in adults from three different families affected with the disease. [1] From this first description only four other families have been described worldwide. [2-5]

In vitro assays demonstrated that CD73-deficient fibroblasts reduced extracellular adenosine levels and enhanced the activity of tissue non-specific alkaline phosphatase (TNAP), which generates procalcifying extracellular Pi. CALJA is an adult-onset disease, with the first symptoms occurring during the second decade of life. The pathogenetic calcification progresses for years, possibly leading to neovascularization and development of small collateral vessels. This fact could explain the marked decrease of ABI index with a mild functional impairment of our patient.

An approved therapy for patients affected by Arterial Calcification due to Deficiency of CD73 has not yet

been available, however an ongoing clinical trial is testing the effectiveness and the safety of Etidronate as a standard treatment for this syndrome.

Table. PCR primers used for Sanger sequencing of NT5E gene

Name	Sequence
NT5E-1F	5'-cctagctgctcgcccctactc
NT5E-1R	5'-actctgccatccgctgcttttc
NT5E-2F	5'-tgtctcatagagcttagtcagttttga
NT5E-2R	5'-ataatgccaagctgtgatttagggc
NT5E-3F	5'-ttaaggtgtttaacctttgcatgta
NT5E-3R	5'-agttacaaaggcaaaagagacacag
NT5E-4F	5'-agccatgtatgtacaagggtgac
NT5E-4R	5'-ggagcaaaatatccagccatctaa
NT5E-5F	5'-ccagaatttagcccagtgtagat
NT5E-5R	5'-tcgcatccttctctctctcc
NT5E-6F	5'-gatcctaaggaagaagagccaga
NT5E-6R	5'-ggcaagaaccataacagaaaagga
NT5E-7F	5'-atcttctcaagtctatctctctct
NT5E-7R	5'-aggaaatgccatgagacttgaggga
NT5E-8F	5'-gaaatctccctttggatctgggtg
NT5E-8R	5'-cttgcccaatcttctgttctct
NT5E-9F	5'-acaaaggactacctactgttgattga
NT5E-9R	5'-agcctgtaaagatggtttttgctg

Note: PCR conditions were identical for all amplimers. PCR was performed using the KAPA DNA PCR kit (Roche Diagnostics, Risch-Rotkreuz, Switzerland) under the specified conditions and 50 ng of genomic DNA. We performed a touch-down PCR using the following protocol: 95°C 3min; 14 cycles 95°C15 sec, 63°C 15sec, 72°C 3sec; 29 cycles 95°C15 sec, 63°C-0.5°C/cycle 15sec, 72°C 3sec. Final extension 72°C 1 min. PCR products were purified using ExoSAP, cycle sequenced and run on a 3130XL ABI Prism apparatus (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA).

LEARNING POINTS/TAKE HOME MESSAGES

- *Arterial Calcification due to Deficiency of CD73 is a rare genetic syndrome secondary to NT5E gene mutation characterized by arterial calcification which selectively targets vessels below the diaphragm together with periarticular calcification.*
- *A complete imaging evaluation with Duplex-ultrasounds, CT-scan and X-ray is of utmost importance to identify the typical arterial and articular calcification pattern.*
- *Arterial Calcification due to Deficiency of CD73 treatment is still a challenge with bisphosphonates as the only pharmacological therapy under evaluation by clinical trials.*

REFERENCES

1. St Hilaire C., Ziegler S.G., Markello T.C., et al. NT5E mutations and arterial calcifications. *N Engl J Med* 2011;364(5):432–42.
2. Ichikawa N1, Taniguchi A, Kaneko H et al. Arterial Calcification Due to Deficiency of CD73 (ACDC) As One of Rheumatic Diseases Associated With Periarticular Calcification. *J Clin Rheumatol*. 2015;21(4):216-20.
3. Zhang Z., He J.W., Fu W.Z, et al. Calcification of joints and arteries: second report with novel NT5E mutations and expansion of the phenotype. *J Hum Genet*. 2015 Oct;60(10):561-4.
4. de Nijs T., Albuissou J., Ockeloen C. W. Isolated arterial calcifications of the lower extremities: A clue for NT5E mutation. *Int J Cardiol* 2016;212: 248-250.
5. Yoshioka K, Kuroda S, Takahashi K. Calcification of joints and arteries with novel NT5E mutations with involvement of upper extremity arteries. *Vasc Med* 2017; 22(6):541-543.

FIGURES

Figure 1. Imaging panel showing wide calcification of the common femoral artery with signs of partial demodulated blood flow on echocolorDoppler scan (panel A) with distal evidence of post-stenotic flow (panel B); X-ray (panel C) and CT scan (panel D) of both legs displaying the typical pattern of massive arterial calcification with several collateral vessels.

Figure 2. Family pedigree and electropherograms of the pathogenic *NT5E* gene variant in exon 9.

PATIENT'S PERSPECTIVE

INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT OR LICENCE STATEMENT

I, **Alfredo Brusco**, the Author has the right to grant and does grant on behalf of all authors, an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the relevant stated licence terms for US Federal Government Employees acting in the course of the their employment, on a worldwide basis to the BMJ Publishing Group Ltd ("BMJ") and its licensees, to permit this Work (as defined in the below licence), if accepted, to be published in BMJ Case Reports and any other BMJ products and to exploit all rights, as set out in our licence [author licence](#).

Date: 09/03/2020

Figure 1




Figure 2

